Recent Updates
Recently added Catalysts
SKYE Negative Sentiment Score: 25/100

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Key Takeaway: Skye Bioscience, Inc. (SKYE) is currently under investigation by Bronstein, Gewirtz & Grossman, LLC, regarding potential claims from investors following the company's unsuccessful Phase 2a clinical trial of its SBI-100 Ophthalmic Emulsion. The trial did not achieve its primary goal of lowering intraocular pressure in patients with glaucoma. As a result, Skye intends to halt clinical development related to SBI-100 and refocus resources on its metabolic program. Subsequently, the company's stock experienced an 8.78% drop after the announcement.

Market Sentiment Analysis

CONCERNS & RISKS

  • Skye's Phase 2a clinical trial did not meet its primary endpoint, impacting its developmental prospects.
  • The company plans to discontinue all R&D related to SBI-100 and its ophthalmology pipeline.
  • Skye's stock price dropped 8.78% following the disappointing trial results.

Full Press Release Details

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SKYE.
Investigation Details
On June 10, 2024, Skye issued a press release, “announcing that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion (“OE”) in patients with primary open-angle glaucoma (“POAG”) or ocular hypertension (“OHT”) did not meet its primary endpoint for lowering intraocular pressure (“IOP”). Skye intends to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027.” Following this news, Skye stock dropped 8.78% on the same day.
If you are aware of any facts relating to this investigation or purchased Skye securities, you can assist this investigation by visiting the firm’s site: bgandg.com/SKYE. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What is the current investigation about Skye Bioscience?

Bronstein, Gewirtz & Grossman, LLC is investigating claims for Skye investors following its Phase 2a trial failure.

Why did Skye's stock price drop recently?

Skye's stock fell 8.78% after it announced its clinical trial for SBI-100 Ophthalmic Emulsion didn't meet its primary endpoint.

How can I assist the investigation into Skye?

Investors can visit bgandg.com/SKYE for more information and to share relevant facts.

Is there a cost to participate in the investigation?

There is no cost; the firm operates on a contingency fee basis, recovering fees only if successful.

What achievements does Bronstein, Gewirtz & Grossman have?

The firm is nationally recognized and has recovered hundreds of millions for investors nationwide.

Last updated: Aug 19, 2024